跳至主要内容
临床试验/NCT05483374
NCT05483374招募中不适用

The Observational Clinical Registry of the European Reference Network on Rare Adult Solid Cancers: the Protocol for the Rare Head and Neck Cancers

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano19 个研究点 分布在 5 个国家目标入组 13,600 人开始时间: 2022年5月31日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
13,600
试验地点
19
主要终点
Percentage of patients treated according to clinical practice guidelines for head and neck cancer

研究概览

简要总结

Cancer care for head and neck cancers is multidisciplinary and complex and knowledge on the rare ones is limited. There is a wide consensus that to support clinical research on rare cancers, clinical registries should be developed within networks specializing in rare cancers. Our hypothesis is that our head and neck cancer registry established in the framework of the European reference network on rare adults solid cancers will help to: describe the natural history of rare head and neck cancers; evaluate factors that influence prognosis; assess treatment effectiveness; measure indicators of quality of care.

The registry is a prospective observational real-world registry. It collects data from already available registries/database and/or directly from expert health care providers (HCP). Information are prospectively collected on patient characteristics; exposure, outcomes and potential confounders (https://euracan.eu/research/starter/rare-head-and-neck-cancer-registry/#codebook).

The registry if federated (i.e. data are stored by the data provider). Analyses will be performed using the federated learning approach which split computations into a local part and a central part. The data providers will share sub-computations only. Data quality checks are envisioned to assess whether data value are present, valid and believable. Validity and plausibility checks are embedded in the electronic case report form (CRF) in the form of alerts and errors during the data input. Additional checks are implemented in R and run using the federated learning to ensure a central data quality monitoring. The data analyses will include descriptive statistics showing frequency and patterns of patients' and cancers' variables; analytical analyses investigating the association of patients/disease and/or treatment characteristics and health outcomes.

Fondazione IRCCS Istituto Nazionale dei Tumori (INT) is the coordinator of the EURACAN registry as well as a data provider. At the INT, and at each HCP involved, responsible investigators ensure that the EURACAN registry will be implemented in compliance with the protocol, following the instructions and procedures described herein. Each HCP is a controller and will identify a data processor. The processing of patients' personal data taking part in the registry is compliant with local privacy legislation and the General Data Protection Regulation 2016/679 of the EU.

详细描述

Despite the rarity of each of the 198 identified rare cancers, collectively they represent 24% of all new cancer cases diagnosed in the EU28/yearly. Differences in survival for rare cancers exist across European countries suggesting the existence of inequalities in healthcare. Rare cancers in general get less scientific consideration and financial support than their more common counterparts. The generation of clinical evidence is more difficult due to the difficulties of conducting clinical trials for to the small number of patients and the paucity of accessible data, including data from cancer registries.

There is a wide consensus that to support clinical research on rare cancers, clinical registries should be developed within networks specializing in rare cancers. In the EU, a unique opportunity is provided by the European Reference Networks (ERNs). The ERNs are virtual networks of selected institutions targeting rare conditions. Three ERNs are dedicated to rare cancers: EuroBloodNet for rare haematological diseases, PaedCan for paediatric cancers and EURACAN for rare adult solid cancers ( https://euracan.eu/).

An EU-supported project Starting an Adult Rare Tumour Registry (STARTER) began on April 1st 2020 to develop the EURACAN registry. The registry initiated on the rare head and neck cancers including nasal cavity and paranasal sinuses (incidence rate 0.5/100,000), nasopharynx (incidence rate 0.5/100,000), salivary gland (incidence rate 1.5/100,000) and middle ear cancers (incidence rate 0.03/100,000), corresponding to 2,500, 2,500, about 8,000 and about 200 new cases/year in Europe, respectively (http://rarecarenet.istitutotumori.mi.it/analysis.php). Cancer care for head and neck cancers is complex in particular for the rare ones. Knowledge is limited, diseases are complex and often need multidisciplinary approach. Moreover, while most head and neck cancers are predominantly squamous cell carcinomas, salivary gland tumours include more than 20 distinct histological subtypes. Thus, heterogeneity add complexity to the rarity.

Against this background, the EURACAN registry on rare head and neck cancers was set up with the following objectives:

  1. to help describe the natural history of rare head and neck cancers;
  2. to evaluate factors that influence prognosis;
  3. to assess treatment effectiveness;
  4. to measure indicators of quality of care.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with epithelial tumours of nasopharynx; nasal cavity and paranasal sinuses; salivary gland cancer in large and small salivary glands; and middle ear (i.e. squamous carcinoma; adenocarcinoma; neuroendocrine; adenosquamous carcinoma, teratocarcinosarcoma, NUT carcinoma, odontogenic tumors) + neuroendocrine and adenocarcinoma in hypopharynx; oropharynx; larynx; oral cavity and lip + odontogenic carcinoma in oral cavity.
  • Adult patients (aged ≥18 years).
  • Diagnosis performed or verified by the expert centre entering the patient information in the registry.
  • Patients entering the HCP at any clinical phase of the disease (diagnosis, treatment of primary cancer, treatment of recurrence, treatment of M+ etc.). The HCP can decide, based on its resources, the number of patients on whom it can collect data.
  • New patients managed by the HCP from 2021 onwards plus patients managed by the HCP, who are actively followed up at the hospital, with year of diagnosis dating back to maximum 2018.

排除标准

  • Patients (aged < 18 years)

研究组 & 干预措施

epithelial tumours of nasal cavity and paranasal sinus

adult patients diagnosed with nasal cavity and paranasal sinus cancers (any stage of disease)

干预措施: observation (Other)

epithelial tumours of nasopharynx

adult patients diagnosed with nasopharyngeal cancers (any stage of disease)

干预措施: observation (Other)

minor and major salivary gland tumours

adult patients diagnosed with minor or major salivary gland cancers (any stage of disease)

干预措施: observation (Other)

middel ear tumours

adult patients diagnosed with cancers of the middle ear (any stage of disease)

干预措施: observation (Other)

结局指标

主要结局

Percentage of patients treated according to clinical practice guidelines for head and neck cancer

时间窗: 1 year

Adherence to clinical practice guidelines

Overall survival

时间窗: 1 year

The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive

Percentage of patients with surgical complications as assessed by the Clavien-Dindo Classification

时间窗: 1 year

Any deviation from the ideal postoperative course that is not inherent in the procedure and does not comprise a failure to cure.

Disease free survival

时间窗: 1 year

The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.

Incidence of cancer treatment adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE)

时间窗: 1 year

Any unexpected medical problem that happens during treatment with a drug or other therapy.

The percentage of patients whose cancer shrinks or disappears after treatment. Treatment response expressed as a complete response; partial response; stable disease; progression based on clinical judgment on imaging.

时间窗: 1 year

A change related to treatment

次要结局

未报告次要终点

研究者

发起方
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
申办方类型
Other
责任方
Principal Investigator
主要研究者

Annalisa Trama

Head of the Epidemiology Valutative Unit

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

研究点 (19)

Loading locations...

相似试验